Single-arm phase II trial is a key component for developing advanced cancer drug and treatment to target therapy and immunotherapy in which time-to-event endpoints are the primary endpoints. The proposed book provides a comprehensive summary to the most commonly used methods for single-arm phase II trial design with time-to-event endpoints.